The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | Recent developments in the treatment of NSCLC
Robin Cornelissen, MD, PhD, Erasmus University Rotterdam, Rotterdam, Netherlands, comments on current developments in the field of non-small cell lung cancer treatment, including neoadjuvant and adjuvant immunotherapy in combination with chemotherapy prior to surgery, as well as multi-targeted tyrosine kinase inhibitors (TKIs) that are able to modulate the tumor microenvironment. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
